Chao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Wu has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Jesse Joshua Smith
Department of Surgery, Colorectal Surgery Service, Memorial Sloan Kettering Cancer Center, New York, USA
23 shared publications - Julio Garcia-Aguilar
Colorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
13 shared publications - Bryan Szeglin
Johns Hopkins University 1 Department of Cell Biology, School of Medicine Baltimore, Maryland
11 shared publications Francisco Sanchez-Vega
10 shared publicationsJinru Shia
10 shared publications- Charles-Etienne Gabriel Sauvé
Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York
9 shared publications
Latest Publications
- Open Access
- 29 August 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (10) , 699-700
Novel organoid culture condition: modeling fetal-like plasticity in colorectal cancer
- 29 August 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (10) , 699-700
Open AccessNovel organoid culture condition: modeling fetal-like plasticity in colorectal cancer
- Open Access
- 5 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102238
Enhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection
- 5 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102238
Open AccessEnhancing chemotherapy response prediction via matched colorectal tumor-organoid gene expression analysis and network-based biomarker selection
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
KRAS mutation in colorectal cancer is associated with aggressive tumor behavior through increased invasiveness and higher rates of lung metastases, but the biological mechanisms behind these features are not fully understood. In this study, we show that KRAS-mutant colorectal cancer upregulates integrin α6β4 through ERK/MEK signaling. Knocking-out integrin β4 (ITGB4) specifically depleted the expression of integrin α6β4 and this resulted in a reduction in the invasion and migration ability of the cancer cells. We also observed a reduction in the number and area of lung metastatic foci in mice that were injected with ITGB4 knockout KRAS-mutant colorectal cancer cells compared with the mice injected with ITGB4 wild-type KRAS-mutant colorectal cancer cells, while no difference was observed in liver metastases. Inhibiting integrin α6β4 in KRAS-mutant colorectal cancer could be a potential therapeutic target to diminish the KRAS-invasive phenotype and associated pulmonary metastasis rate.Implications:Knocking-out ITGB4, which is overexpressed in KRAS-mutant colorectal cancer and promotes tumor aggressiveness, diminishes local invasiveness and rates of pulmonary metastasis.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
KRAS mutation in colorectal cancer is associated with aggressive tumor behavior through increased invasiveness and higher rates of lung metastases, but the biological mechanisms behind these features are not fully understood. In this study, we show that KRAS-mutant colorectal cancer upregulates integrin α6β4 through ERK/MEK signaling. Knocking-out integrin β4 (ITGB4) specifically depleted the expression of integrin α6β4 and this resulted in a reduction in the invasion and migration ability of the cancer cells. We also observed a reduction in the number and area of lung metastatic foci in mice that were injected with ITGB4 knockout KRAS-mutant colorectal cancer cells compared with the mice injected with ITGB4 wild-type KRAS-mutant colorectal cancer cells, while no difference was observed in liver metastases. Inhibiting integrin α6β4 in KRAS-mutant colorectal cancer could be a potential therapeutic target to diminish the KRAS-invasive phenotype and associated pulmonary metastasis rate.Implications:Knocking-out ITGB4, which is overexpressed in KRAS-mutant colorectal cancer and promotes tumor aggressiveness, diminishes local invasiveness and rates of pulmonary metastasis.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Table from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
KRAS mutation in colorectal cancer is associated with aggressive tumor behavior through increased invasiveness and higher rates of lung metastases, but the biological mechanisms behind these features are not fully understood. In this study, we show that KRAS-mutant colorectal cancer upregulates integrin α6β4 through ERK/MEK signaling. Knocking-out integrin β4 (ITGB4) specifically depleted the expression of integrin α6β4 and this resulted in a reduction in the invasion and migration ability of the cancer cells. We also observed a reduction in the number and area of lung metastatic foci in mice that were injected with ITGB4 knockout KRAS-mutant colorectal cancer cells compared with the mice injected with ITGB4 wild-type KRAS-mutant colorectal cancer cells, while no difference was observed in liver metastases. Inhibiting integrin α6β4 in KRAS-mutant colorectal cancer could be a potential therapeutic target to diminish the KRAS-invasive phenotype and associated pulmonary metastasis rate.Implications:Knocking-out ITGB4, which is overexpressed in KRAS-mutant colorectal cancer and promotes tumor aggressiveness, diminishes local invasiveness and rates of pulmonary metastasis.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
KRAS mutation in colorectal cancer is associated with aggressive tumor behavior through increased invasiveness and higher rates of lung metastases, but the biological mechanisms behind these features are not fully understood. In this study, we show that KRAS-mutant colorectal cancer upregulates integrin α6β4 through ERK/MEK signaling. Knocking-out integrin β4 (ITGB4) specifically depleted the expression of integrin α6β4 and this resulted in a reduction in the invasion and migration ability of the cancer cells. We also observed a reduction in the number and area of lung metastatic foci in mice that were injected with ITGB4 knockout KRAS-mutant colorectal cancer cells compared with the mice injected with ITGB4 wild-type KRAS-mutant colorectal cancer cells, while no difference was observed in liver metastases. Inhibiting integrin α6β4 in KRAS-mutant colorectal cancer could be a potential therapeutic target to diminish the KRAS-invasive phenotype and associated pulmonary metastasis rate.Implications:Knocking-out ITGB4, which is overexpressed in KRAS-mutant colorectal cancer and promotes tumor aggressiveness, diminishes local invasiveness and rates of pulmonary metastasis.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer
Supplementary Figure from KRAS Mutants Upregulate Integrin β4 to Promote Invasion and Metastasis in Colorectal Cancer